echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Blood System > Professor Liang Aibin: New targeted drug selinexor brings new hope to DLBCL patients

    Professor Liang Aibin: New targeted drug selinexor brings new hope to DLBCL patients

    • Last Update: 2021-11-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Professor Liang Aibin, Doctoral Supervisor, Professor, Deputy Dean of Tongji Hospital, Director of Hematology Oncology Center, Deputy Secretary-General of the Experimental Hematology Committee of the Chinese Pathophysiological Society Member of the Hematology Branch of the Chinese Medical Association Member of the National Standing Committee of the Chinese Medical Doctor Association Shanghai Medical Association Hematology Branch Candidate Chairman, Shanghai Medical Doctor Association, Hematology Branch, Vice Chairman, Shanghai Anti-Cancer Association, Hematology Branch, Deputy Chairman, Shanghai Immunological Society, Hematology Committee, Deputy Chairman, National-level young and middle-aged expert with outstanding contributions, and enjoys a special allowance from the State Council "Hundred Thousand" National-level candidate of the "Ten Thousand Talents Project" 2020 Saint-Antoine-EBMT Youth Leader; the 4th "National Famous Doctor, Excellent Demeanor" title; 2019 National Health Commission Stroke Prevention Project Model Dean; Scientific Chinese 2018 Person; "New Century Outstanding Talents" Program of the Ministry of Education; 2012 "National Health System Excellent Workers"; Shanghai Outstanding Subject Leaders, Leading Talents, "Science and Technology Stars"; Second Prize of "Silver Snake Award" and "Dawn of Light" And many other honors
    .

    Presided over more than 30 national, provincial and ministerial scientific research projects, won 5 scientific and technological achievement awards, published more than 200 papers, including more than 80 SCI papers, participated in the compilation of 4 books and the formulation of consensus on CART cell therapy toxicity
    .

    Professor Li Ping, Chief Physician of the Department of Hematology, Shanghai Tongji Hospital, Ph.
    D.
    of Master's Supervisor, Nagoya University, Postdoctoral Fellow, Aichi Cancer Hospital, Japan, Youth Committee of the Hematology Branch of the Chinese Medical Association Committee Member, Biotherapeutics Committee, Chinese Research Hospital Association, Youth Committee, Hematological Transformation Committee, China Anti-Cancer Association, Youth Committee, Hematology Committee, Chinese Rehabilitation Medicine Association, Deputy Chairman, Lymphoma Professional Youth Committee, Shanghai Anti-Cancer Association, Shanghai Society of Hematology Member of the Laboratory Diagnosis Group Member of the Blood Immunity Committee of Shanghai Society of Immunology, mainly engaged in diagnosis and treatment of lymphatic tumors and CART immunotherapy for the past 5 years
    .

    Currently presides over 2 National Natural Science Foundation of China, participated in several national projects and Shanghai Science and Technology Commission projects, and published more than 30 papers
    .

    Poke "read the original text", we make progress together
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.